EAU 2024: Photocure Partner Asieris to present the Drug and Equipment Performance Results from the Chinese Phase III Clinical Study of Hexvix in Combination with HD 4K Blue Light Cystoscopy equipment

Published: 1 April 2024Medical congresses & eventsMedical InformationPartnership News & Expansion

Oslo, Norway, April 1, 2024: Photocure ASA, The Bladder Cancer Company, announces that its partner Asieris plans to unveil the drug and equipment performance results from the Phase III clinical study of Hexvix (bladder cancer diagnostic and management drug - APL-1706) in combination with HD 4K blue light cystoscopy equipment at the 39th Annual Meeting of the European Association of Urology (EAU), April 5-8, 2024 in Paris. The oral abstract presentation is scheduled for April 8. 

Abstract Title: A prospective, comparative, within-patient controlled multicenter phase III study comparing blue light cystoscopy in combination with APL-1706 versus white light cystoscopy for the detection of bladder cancer using modern HD 4K equipment

See Asieris’ full release here: https://asieris.com/asieris-pharmaceuticals-to-present-the-drug-and-equipment-performance-results-from-the-phase-iii-clinical-study-of-the-bladder-cancer-diagnostic-and-management-drug-apl-1706-in-combination-with-hd-4k/

News and events